SEC Comment Letter 0000000000-25-003036 to ProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics N.V.
Date: March 20, 2025 · CIK: 0001612940 · Accession: 0000000000-25-003036
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285767
Letter
Re: ProQR Therapeutics N.V. Registration Statement on Form F-3 Filed March 13, 2025 File No. 333-285767 Dear Daniel de Boer:
March 20, 2025
Daniel de Boer Chief Executive Officer ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Adam V. Johnson, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 20, 2025 Daniel de Boer Chief Executive Officer ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Re: ProQR Therapeutics N.V. Registration Statement on Form F-3 Filed March 13, 2025 File No. 333-285767 Dear Daniel de Boer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Adam V. Johnson, Esq. </TEXT> </DOCUMENT>